Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) Profit After Tax: 2020-2024

Historic Profit After Tax for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Dec 2024 value amounting to -$115.6 million.

  • Tarsus Pharmaceuticals' Profit After Tax rose 46.26% to -$12.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.2 million, marking a year-over-year increase of 39.59%. This contributed to the annual value of -$115.6 million for FY2024, which is 14.97% up from last year.
  • Tarsus Pharmaceuticals' Profit After Tax amounted to -$115.6 million in FY2024, which was up 14.97% from -$135.9 million recorded in FY2023.
  • In the past 5 years, Tarsus Pharmaceuticals' Profit After Tax registered a high of -$13.8 million during FY2021, and its lowest value of -$135.9 million during FY2023.
  • Its 3-year average for Profit After Tax is -$104.5 million, with a median of -$115.6 million in 2024.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Profit After Tax soared by 48.43% in 2021, and later crashed by 349.06% in 2022.
  • Yearly analysis of 5 years shows Tarsus Pharmaceuticals' Profit After Tax stood at -$26.8 million in 2020, then surged by 48.43% to -$13.8 million in 2021, then slumped by 349.06% to -$62.1 million in 2022, then slumped by 118.86% to -$135.9 million in 2023, then rose by 14.97% to -$115.6 million in 2024.